PRESS RELEASE published on 07/09/2025 at 22:05, 1 year ago Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité Nomination R&D Affaires Réglementaires Inventiva Lanifibranor
PRESS RELEASE published on 07/09/2025 at 22:05, 1 year ago Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance Inventiva appoints Jason Campagna as President of R&D and CMO and Martine Zimmermann as EVP of Regulatory Affairs and Quality Assurance, emphasizing long-term growth and operational excellence Quality Assurance R&D Leadership Appointments Regulatory Affairs Inventiva
BRIEF published on 07/07/2025 at 22:05, 1 year ago Inventiva Receives $10 Million Milestone Payment from CTTQ Milestone Payment Lanifibranor Biopharmaceutical Development MASH Treatment CTTQ Partnership
BRIEF published on 07/07/2025 at 22:05, 1 year ago Inventiva reçoit un paiement d'étape de 10 millions de dollars du CTTQ Paiement D'étape Lanifibranor Développement Biopharmaceutique Traitement MASH Partenariat CTTQ
PRESS RELEASE published on 07/07/2025 at 22:00, 1 year ago Inventiva receives $10 million milestone payment from CTTQ Inventiva receives $10 million milestone payment from CTTQ following successful structured financing. Partnership aims to develop lanifibranor for MASH treatment in Chinese regions Inventiva Milestone Payment MASH Lanifibranor CTTQ
PRESS RELEASE published on 07/07/2025 at 22:00, 1 year ago Inventiva receives $10 million milestone payment from CTTQ Inventiva reçoit un paiement d'étape de 10 millions de dollars de la part de CTTQ pour le développement de thérapies contre la stéatohépatite. Accord de licence avec potentiel de 265 millions de dollars supplémentaires Paiement Inventiva Stéatohépatite Thérapies CTTQ
BRIEF published on 07/02/2025 at 22:05, 1 year 1 month ago Inventiva Publishes Promising Results on Lanifibranor for Liver Disease Phase 2b Study Liver Disease Lanifibranor MASH Treatment Journal Of Hepatology Reports
BRIEF published on 07/02/2025 at 22:05, 1 year 1 month ago Inventiva publie des résultats prometteurs sur le lanifibranor pour les maladies du foie Étude De Phase 2b Maladie Du Foie Lanifibranor Traitement MASH Journal Des Rapports D'hépatologie
PRESS RELEASE published on 07/02/2025 at 22:00, 1 year 1 month ago Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease Inventiva announces publication in Journal of Hepatology Reports on lanifibranor treatment effects on liver sinusoidal endothelial cells in MASLD/MASH patients and preclinical models, showing potential therapeutic benefits Inventiva MASH Lanifibranor Journal Of Hepatology Reports LSEC Capillarization
PRESS RELEASE published on 07/02/2025 at 22:00, 1 year 1 month ago Inventiva annonce la publication dans le Journal of Hepatology Reports des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH et dans des modèles précliniques de la maladie Inventiva annonce la publication des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH. Des effets bénéfiques allant au-delà de l'inversion de la capillarisation ont été observés Inventiva MASH MASLD Lanifibranor Cellules Endothéliales
Published on 08/05/2026 at 02:10, 2 hours 16 minutes ago Kleen Hy-Dro-Gen Inc. Is Pleased to Announce Dual ISO 9001:2015 and TSSA Certifications, Bolstering Operational Quality and Technical Safety Governance
Published on 08/04/2026 at 22:30, 5 hours 56 minutes ago Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares
Published on 08/04/2026 at 17:00, 11 hours 26 minutes ago Moderna annonce le début d'un essai clinique de phase 1 portant sur l’ARNm-1469, son vaccin expérimental contre l'ébolavirus de Bundibugyo
Published on 08/04/2026 at 16:25, 12 hours 1 minute ago ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/04/2026 at 22:03, 6 hours 23 minutes ago #FutureFresenius: Excellent Q2 performance demonstrates structural step-up – Guidance raised
Published on 08/04/2026 at 22:01, 6 hours 25 minutes ago EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
Published on 08/04/2026 at 20:05, 8 hours 21 minutes ago Hard Rock Cafe and Coca-Cola® Launch Hard Rock Rising Music Competition for Emerging Artists
Published on 08/04/2026 at 19:39, 8 hours 47 minutes ago EQS-Adhoc: Basler AG financial results for the first 6 months of 2026: Strong business performance in the first half of the year; company raises its 2026 forecast once again
Published on 08/04/2026 at 18:32, 9 hours 54 minutes ago Capital et droits de vote au 31 juillet 2026
Published on 08/04/2026 at 18:32, 9 hours 54 minutes ago Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 10 hours 41 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL